Literature DB >> 3137245

Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B-producing Staphylococcus aureus.

S M Opal1, A D Johnson-Winegar, A S Cross.   

Abstract

An exfoliatin B-producing strain of Staphylococcus aureus was isolated from two adults with typical staphylococcal scalded skin syndrome (SSSS). One patient developed desquamation after a local staphylococcal infection of the hand, and the other developed exfoliation after nosocomially acquired staphylococcal endocarditis. Neither patient was immunocompromised, had evidence of renal insufficiency, or manifested other potential risk factors for SSSS. Purified toxin, isolated from the causative organisms, produced a Nikolsky sign in neonatal mice. The toxins were shown to be exfoliatin B by biochemical and immunologic methods and heretofore had been described only in children with SSSS. Analysis of plasmid DNAs from both strains revealed a 23-megadalton plasmid with identical restriction endonuclease digestion fragments. One isolate belonged to phage group II (3B/3C/6/7/47/54/55), whereas the other isolate belonged to phage groups I and III (7/29/52/52A/53/54/80). The observation that a non-phage group II exfoliatin-producing strain of S. aureus may produce SSSS in adults indicates the need to better define the diagnostic criteria for SSSS. Immunocompetent adults may remain susceptible to some strains of exfoliatin B-producing S. aureus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137245      PMCID: PMC266593          DOI: 10.1128/jcm.26.7.1283-1286.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Toxic epidermal necrolysis. Rapid differentiation between staphylococcal- and drug-induced disease.

Authors:  R B Amon; R L Dimond
Journal:  Arch Dermatol       Date:  1975-11

2.  Detection of anti-exfoliatin antibodies in healthy adults and children by the passive hemagglutination test.

Authors:  Y Sarai; H Nakahara; T Ishikawa; I Kondo; S Futaki
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

3.  Staphylococcal scalded skin syndrome: detection of antibody to epidermolytic toxin by a primary binding assay.

Authors:  D H Baker; K D Wuepper; J E Rasmussen
Journal:  Clin Exp Dermatol       Date:  1978-03       Impact factor: 3.470

4.  Staphylococcus aureus: some host-parasite interactions.

Authors:  F A Kapral
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

5.  The staphylococcal scalded-skin syndrome.

Authors:  M E Melish; L A Glasgow
Journal:  N Engl J Med       Date:  1970-05-14       Impact factor: 91.245

6.  Staphylococcal scalded skin syndrome. Clinical features, pathogenesis, and recent microbiological and biochemical developments.

Authors:  P M Elias; P Fritsch; E H Epstein
Journal:  Arch Dermatol       Date:  1977-02

7.  Two serotypes of exfoliatin and their distribution in staphylococcal strains isolated from patients with scalded skin syndrome.

Authors:  I Kondo; S Sakurai; Y Sarai; S Futaki
Journal:  J Clin Microbiol       Date:  1975-05       Impact factor: 5.948

8.  New type of exfoliatin obtained from staphylococcal strains, belonging to phage groups other than group II, isolated from patients with impetigo and Ritter's disease.

Authors:  I Kondo; S Sakurai; Y Sarai
Journal:  Infect Immun       Date:  1974-10       Impact factor: 3.441

9.  Nursery outbreak of scalded-skin syndrome. Scarlatiniform rash due to phage group I Staphylococcus aureus.

Authors:  H S Faden; J P Burke; L A Glasgow; J R Everett
Journal:  Am J Dis Child       Date:  1976-03

10.  Staphylococcal scalded skin syndrome in a homosexual adult.

Authors:  M Richard; A Mathieu-Serra
Journal:  J Am Acad Dermatol       Date:  1986-08       Impact factor: 11.527

View more
  9 in total

1.  Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins.

Authors:  Osamu Yamasaki; Takayuki Yamaguchi; Motoyuki Sugai; Colette Chapuis-Cellier; François Arnaud; François Vandenesch; Jerome Etienne; Gerard Lina
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 2.  Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome.

Authors:  S Ladhani; C L Joannou; D P Lochrie; R W Evans; S M Poston
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Screening of Staphylococcus aureus nasal strains isolated from medical students for toxin genes.

Authors:  L Piechowicz; K Garbacz; K Wiśniewska; M Dąbrowska-Szponar
Journal:  Folia Microbiol (Praha)       Date:  2011-05-31       Impact factor: 2.099

4.  Staphylococcal Scalded Skin Syndrome: Criteria for Differential Diagnosis from Lyell's Syndrome. Two Cases in Adult Patients.

Authors:  B Napoli; N D'Arpa; L D'Amelio; S Chimenti; D Pileri; A Accardo-Palumbo; F Conte
Journal:  Ann Burns Fire Disasters       Date:  2006-12-31

Review 5.  The epidermolytic (exfoliative) toxins of Staphylococcus aureus.

Authors:  C J Bailey; B P Lockhart; M B Redpath; T P Smith
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402

6.  Staphylococcal scalded skin syndrome in an immunocompromised adult.

Authors:  E Roeb; T Schönfelder; S Matern; H G Sieberth; W Lenz; R Lütticken; R R Reinert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

7.  Functional evidence that the Ser-195 residue of staphylococcal exfoliative toxin A is essential for biological activity.

Authors:  G Prévost; S Rifai; M L Chaix; Y Piémont
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

8.  A double outbreak of exfoliative toxin-producing strains of Staphylococcus aureus in a maternity unit.

Authors:  J Dave; S Reith; J Q Nash; R R Marples; C Dulake
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

Review 9.  Exfoliative toxins of Staphylococcus aureus.

Authors:  Michal Bukowski; Benedykt Wladyka; Grzegorz Dubin
Journal:  Toxins (Basel)       Date:  2010-05-25       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.